Edmond DE Rothschild Holding S.A. Takes Position in Kenvue Inc. $KVUE

Edmond DE Rothschild Holding S.A. bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to its most recent filing with the SEC. The fund bought 900,000 shares of the company’s stock, valued at approximately $17,199,000.

Other institutional investors also recently added to or reduced their stakes in the company. AssuredPartners Investment Advisors LLC purchased a new stake in Kenvue during the second quarter worth about $625,000. Johnson Financial Group Inc. purchased a new position in Kenvue in the second quarter valued at about $26,000. Tocqueville Asset Management L.P. purchased a new position in Kenvue in the second quarter valued at about $30,302,000. NewEdge Wealth LLC bought a new position in shares of Kenvue during the 2nd quarter valued at approximately $1,026,000. Finally, Great Lakes Advisors LLC purchased a new stake in shares of Kenvue during the 2nd quarter worth approximately $1,503,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

KVUE has been the topic of several research analyst reports. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Barclays upped their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. UBS Group cut their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Finally, Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $19.27.

Kenvue Stock Up 1.9%

KVUE opened at $19.16 on Thursday. The company has a 50 day moving average of $19.02 and a 200 day moving average of $18.18. The company has a market cap of $36.80 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 1.35 and a beta of 0.47. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $21.84. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.29 EPS. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.